Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma

Cancer Research

Volumn 64, Issue 19, 2004, Pages 6883-6891

  Wei, Jun S ^a   Greer, Braden T ^a   Westermann, Frank ^b   Steinberg, Seth M ^a   Son, Chang Gue ^a,c   Chen, Qing Rong ^a   Whiteford, Craig C ^a   Bilke, Sven ^a   Krasnoselsky, Alexei L ^a   Cenacchi, Nicola ^a   Catchpoole, Daniel ^d   Berthold, Frank ^e   Schwab, Manfred ^b   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Daejeon University   (South Korea)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HERMES ANTIGEN; MELPHALAN; VINCRISTINE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; NEUROBLASTOMA; ONCOGENE MYC; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEURAL NETWORKS (COMPUTER); NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4944248113     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0695     Document Type: Article

References (42)

1. Brodeur GM, Maris JM. Neuroblastoma. In: PA Pizzo and DG Poplack, editors. Principles and practice of pediatric oncology, 4th ed. Philadelphia: Lipptncott-Raven; 2002. p. 895-937.
2. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
3. Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 2002;184:127-47.
4. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
5. Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
6. Pearson AD, Philip T. Prognosis of low-risk and high-risk neuroblastoma. In: GM Brodeur, T Sawada, Y Tsuchida, PA Voute, editors. Neuroblastoma, 1st ed. Amsterdam, The Netherlands: Elsevier Science; 2000. p. 555.
7. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-9.
8. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98:15149-54.
9. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond) 2002;415:530-6.
10. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (Lond) 2002;415:436-42.
11. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
12. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-7.
13. Wei JS, Khan J. Purification of total RNA from mammalian cells and tissues. In: D Bowtell, J Sambrook, editors. DNA microarrays: a molecular cloning manual. Cold Spring Harbor. New York: Cold Spring Harbor Laboratory Press; 2002. p. 110-9.
14. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002;4:30-6.
15. Hegde P, Qi R, Abernathy K, et al. A concise guide to cDNA microarray analysis. Biotechniques 2000;29:548-50, 552-4, 556 passim.
16. Chen Y, Dougherty ER, Bittner ML. Ratio-based decisions and the quantitative analysis of cDNA microarray images. Biomedical Optics 1997;2:364-74.
17. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, Trent JM. Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 2002;18:1207-15.
18. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 1966;50:163-70.
20. Cox D. Regression models and life tables. J Royal Stat Soc (B) 1972;34:187-202.
21. Matthews DE, Farewell VT. Using and understanding medical statistics. 3rd ed. Basel: Karger, 1996. p. 150-60.
22. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
23. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
24. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996;14:25-34.
25. Munchar MJ, Sharifah NA, Jamal R, Looi LM. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours. Pathology 2003;35:125-9.
26. Pinkerton CR, Blanc Vincent MP, Bergeron C, Fervers B, Philip T. Induction chemotherapy in metastatic neuroblastoma - does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000;36:1808-15.
27. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984;81:4940-4.
28. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-6.
29. Nisen PD, Waber PG, Rich MA, Pierce S, Garvin JR Jr, Gilbert F, Lanzkowsky P. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-7.
30. Slave I, Ellenbogen R, Jung WH, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50:1459-63.
31. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-94.
32. Bettenhausen B, Hrabe de Angelis M, Simon D, Guenet JL, Gossler A. Transient and restricted expression during mouse embryogenesis of DIII, a murine gene closely related to Drosophila Delta. Development 1995;121:2407-18.
33. Helman LJ, Thiele CJ, Linehan WM, Nelkin BD, Baylin SB, Israel MA. Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci USA 1987;84:2336-9.
34. van Limpt V, Chan A, Caron H, et al. SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene. Med Pediatr Oncol 2000;35:554-8.
35. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (Wash DC) 1999;284:770-6.
36. Lyford GL, Yamagata K, Kaufmann WE, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 1995;14:433-45.
37. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development 1997;124:1953-62.
38. Itoh A, Miyabayashi T, Ohno M, Sakano S. Cloning and expressions of three mammalian homologues of Drosophila slit suggest possible roles for Slit in the formation and maintenance of the nervous system. Mol Brain Res 1998;62:175-86.
39. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999;96:214-9.
40. Yuan J, Luo RZ, Fujii S, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers Cancer Res 2003;63:4174-80.
41. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
42. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995;55:1798-806.